Drug Trial Radar · NCT00277914
Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women
Last checked: Nov 20, 2026Latest source record: Mar 16, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
749
Actual
Start
Jan 2006
Primary completion
Jul 2007
Sponsor
- Lead sponsor
- Sprout Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 18, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.
Conditions
- Sexual Dysfunctions, Psychological
Interventions
FlibanserinDrug
flibanserin flexible dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of efficacy of flibanserin in Sexually Satisfying EventsTime frame: 24 weeks
Locations
65 sites in 2 countries. Site status is shown where the registry gives one.
511.74.01051 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
511.74.01027 Boehringer Ingelheim Investigational Site
Mobile, Alabama
511.74.01029 Boehringer Ingelheim Investigational Site
Scottsdale, Arizona
511.74.01031 Boehringer Ingelheim Investigational Site
Tucson, Arizona
511.74.01004 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas
511.74.01053 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
511.74.01033 Boehringer Ingelheim Investigational Site
Palm Springs, California
511.74.01003 Boehringer Ingelheim Investigational Site
Palo Alto, California
511.74.01015 Boehringer Ingelheim Investigational Site
Sacramento, California
511.74.01013 Boehringer Ingelheim Investigational Site
San Diego, California
511.74.01052 Boehringer Ingelheim Investigational Site
Torrance, California
511.74.01022 Boehringer Ingelheim Investigational Site
Aurora, Colorado
511.74.01046 Boehringer Ingelheim Investigational Site
Denver, Colorado
511.74.01002 Boehringer Ingelheim Investigational Site
Groton, Connecticut
511.74.01023 Boehringer Ingelheim Investigational Site
Middlebury, Connecticut
511.74.01009 Boehringer Ingelheim Investigational Site
West Hartford, Connecticut
511.74.01035 Boehringer Ingelheim Investigational Site
Newark, Delaware
511.74.01039 Boehringer Ingelheim Investigational Site
Coral Gables, Florida
511.74.01019 Boehringer Ingelheim Investigational Site
Gainesville, Florida
511.74.01044 Boehringer Ingelheim Investigational Site
Hollywood, Florida
511.74.01001 Boehringer Ingelheim Investigational Site
Hudson, Florida
511.74.01043 Boehringer Ingelheim Investigational Site
Pembroke Pines, Florida
511.74.01032 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
511.74.01036 Boehringer Ingelheim Investigational Site
Roswell, Georgia
511.74.01047 Boehringer Ingelheim Investigational Site
Champaign, Illinois
511.74.01038 Boehringer Ingelheim Investigational Site
Evansville, Indiana
511.74.01014 Boehringer Ingelheim Investigational Site
Lexington, Kentucky
511.74.01007 Boehringer Ingelheim Investigational Site
Baton Rouge, Louisiana
511.74.01024 Boehringer Ingelheim Investigational Site
Rockland, Maine
511.74.01030 Boehringer Ingelheim Investigational Site
Ann Arbor, Michigan
511.74.01056 Boehringer Ingelheim Investigational Site
Bingham Farms, Michigan
511.74.01010 Boehringer Ingelheim Investigational Site
St Louis, Missouri
511.74.01012 Boehringer Ingelheim Investigational Site
Billings, Montana
511.74.01045 Boehringer Ingelheim Investigational Site
Omaha, Nebraska
511.74.01041 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada
511.74.01055 Boehringer Ingelheim Investigational Site
Reno, Nevada
511.74.01018 Boehringer Ingelheim Investigational Site
Poughkeepsie, New York
511.74.01011 Boehringer Ingelheim Investigational Site
Rochester, New York
511.74.01048 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina
511.74.01021 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.